Abstract: Lymphomas are a group of heterogeneous tumors originating from lymphocytes at various stages of differentiation. Epigenetics is an emerging discipline of science that studies heritable changes in the DNA sequences and gene expression patterns of organisms. Studies have shown that the development and progression of lymphomas are closely related to epigenetic abnormalities. Drugs targeting epigenetic abnormalities, including DNA methyltransferase inhibitors, histone deacetylase inhibitors, EZH2 inhibitors, PRMT inhibitors, and BET inhibitors, have been studied extensively and have shown many advantages in the treatment of lymphomas. This article reviews the recent advances in epigenetic drugs for treatment of lymphomas to provide new ideas for treatment strategies for lymphoma.